Merus (MRUS) Competitors $47.37 -0.26 (-0.55%) Closing price 04:00 PM EasternExtended Trading$47.36 -0.01 (-0.02%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MRUS vs. SRPT, PCVX, QGEN, ROIV, ASND, RVMD, BPMC, LEGN, AXSM, and TLXShould you be buying Merus stock or one of its competitors? The main competitors of Merus include Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Qiagen (QGEN), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), and Telix Pharmaceuticals Limited American Depositary Shares (TLX). These companies are all part of the "pharmaceutical products" industry. Merus vs. Sarepta Therapeutics Vaxcyte Qiagen Roivant Sciences Ascendis Pharma A/S Revolution Medicines Blueprint Medicines Legend Biotech Axsome Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Sarepta Therapeutics (NASDAQ:SRPT) and Merus (NASDAQ:MRUS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, community ranking, profitability, risk, media sentiment, earnings and valuation. Does the media refer more to SRPT or MRUS? In the previous week, Sarepta Therapeutics had 2 more articles in the media than Merus. MarketBeat recorded 13 mentions for Sarepta Therapeutics and 11 mentions for Merus. Sarepta Therapeutics' average media sentiment score of 0.99 beat Merus' score of 0.62 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Merus 4 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, SRPT or MRUS? Merus has lower revenue, but higher earnings than Sarepta Therapeutics. Merus is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSarepta Therapeutics$1.24B8.16-$535.98M$1.2585.02Merus$43.95M73.79-$154.94M-$3.95-11.99 Which has more risk and volatility, SRPT or MRUS? Sarepta Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Merus has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Is SRPT or MRUS more profitable? Sarepta Therapeutics has a net margin of 7.43% compared to Merus' net margin of -680.61%. Sarepta Therapeutics' return on equity of 11.00% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets Sarepta Therapeutics7.43% 11.00% 3.35% Merus -680.61%-38.89%-31.16% Do analysts prefer SRPT or MRUS? Sarepta Therapeutics presently has a consensus price target of $176.77, indicating a potential upside of 66.33%. Merus has a consensus price target of $85.92, indicating a potential upside of 81.39%. Given Merus' stronger consensus rating and higher probable upside, analysts clearly believe Merus is more favorable than Sarepta Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 1 Sell rating(s) 2 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.87Merus 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.13 Do institutionals & insiders hold more shares of SRPT or MRUS? 86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 96.1% of Merus shares are held by institutional investors. 7.7% of Sarepta Therapeutics shares are held by insiders. Comparatively, 4.6% of Merus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer SRPT or MRUS? Sarepta Therapeutics received 1108 more outperform votes than Merus when rated by MarketBeat users. Likewise, 75.23% of users gave Sarepta Therapeutics an outperform vote while only 67.30% of users gave Merus an outperform vote. CompanyUnderperformOutperformSarepta TherapeuticsOutperform Votes146475.23% Underperform Votes48224.77% MerusOutperform Votes35667.30% Underperform Votes17332.70% SummarySarepta Therapeutics beats Merus on 12 of the 19 factors compared between the two stocks. Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRUS vs. The Competition Export to ExcelMetricMerusPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.24B$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-11.996.1326.4618.82Price / Sales73.79312.32457.0180.82Price / CashN/A67.8344.0437.47Price / Book7.686.747.634.64Net Income-$154.94M$138.11M$3.18B$245.69M7 Day Performance17.84%-2.02%-1.82%-2.63%1 Month Performance19.20%-1.54%0.22%-2.37%1 Year Performance5.27%-3.14%17.49%13.65% Merus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRUSMerus2.7479 of 5 stars$47.37-0.5%$85.92+81.4%+6.1%$3.24B$43.95M-11.9937SRPTSarepta Therapeutics4.4962 of 5 stars$113.11+1.2%$178.71+58.0%-20.4%$10.82B$1.24B90.591,314Upcoming EarningsPCVXVaxcyte2.5867 of 5 stars$85.95-1.7%$145.71+69.5%+11.3%$10.72BN/A-18.69160Insider TradePositive NewsQGENQiagen4.4279 of 5 stars$40.17-2.8%$48.78+21.4%-7.3%$8.91B$1.98B111.875,967Analyst DowngradeROIVRoivant Sciences2.7251 of 5 stars$10.80-0.9%$17.93+66.1%-7.1%$7.87B$124.79M1.91860Insider TradeASNDAscendis Pharma A/S3.1758 of 5 stars$119.11-1.5%$191.57+60.8%-1.4%$7.26B$288.08M-14.81640Analyst ForecastRVMDRevolution Medicines4.5108 of 5 stars$42.40+0.5%$66.25+56.3%+44.9%$7.15B$11.58M-11.84250BPMCBlueprint Medicines2.9925 of 5 stars$103.13-1.8%$123.72+20.0%+3.4%$6.58B$434.42M-49.06640Earnings ReportLEGNLegend Biotech2.5939 of 5 stars$35.84+1.3%$79.50+121.8%-35.2%$6.56B$285.14M-37.801,800Positive NewsAXSMAxsome Therapeutics4.5264 of 5 stars$127.50+20.6%$134.00+5.1%+59.2%$6.20B$270.60M-19.61380Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$18.10+0.3%$22.00+21.6%N/A$6.06BN/A0.00N/ANews CoverageGap Up Related Companies and Tools Related Companies Sarepta Therapeutics Competitors Vaxcyte Competitors Qiagen Competitors Roivant Sciences Competitors Ascendis Pharma A/S Competitors Revolution Medicines Competitors Blueprint Medicines Competitors Legend Biotech Competitors Axsome Therapeutics Competitors Telix Pharmaceuticals Limited American Depositary Shares Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MRUS) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRUS Stock Alerts